HARBOR study: visual, anatomic improvements maintained at 2 years

Ranibizumab improved vision for 2 years in patients with subfoveal neovascular age-related macular degeneration, according to results of the HARBOR study.The randomized, controlled, multicenter phase 2 study included 1,098 patients 50 years and older with treatment-naïve subfoveal wet AMD.Patients were randomly assigned to one of four groups:  0.5 mg monthly injections (group one), 0.5 mg as needed (group two), 2 mg monthly (group three) or 2 mg as needed (group four).